700 SAGINAW DR, REDWOOD CITY, CA
Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Financial Results, Press Release
Other Events
Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Submission of Matters to a Vote of Security Holders
Enters Into $2 Billion Flexible Funding Agreement to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
Changes in Board, Management or Compensation
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Definitive Merger Proxy Statement
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities